| Inflammatory bowel disease and mutations affecting the interleukin-10 receptor EO Glocker, D Kotlarz, K Boztug, EM Gertz, AA Schäffer, F Noyan, M Perro, ... New England Journal of Medicine 361 (21), 2033-2045, 2009 | 1694 | 2009 |
| Nociceptive sensory neurons drive interleukin-23-mediated psoriasiform skin inflammation L Riol-Blanco, J Ordovas-Montanes, M Perro, E Naval, A Thiriot, ... Nature 510 (7503), 157-161, 2014 | 531 | 2014 |
| A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells G Stary, A Olive, AF Radovic-Moreno, D Gondek, D Alvarez, PA Basto, ... Science 348 (6241), aaa8205, 2015 | 398 | 2015 |
| A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors M Bacac, T Fauti, J Sam, S Colombetti, T Weinzierl, D Ouaret, W Bodmer, ... Clinical Cancer Research 22 (13), 3286-3297, 2016 | 358 | 2016 |
| Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome C Woellner, EM Gertz, AA Schäffer, M Lagos, M Perro, EO Glocker, ... Journal of Allergy and Clinical Immunology 125 (2), 424-432. e8, 2010 | 344 | 2010 |
| Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy M Mayoux, A Roller, V Pulko, S Sammicheli, S Chen, E Sum, C Jost, ... Science translational medicine 12 (534), eaav7431, 2020 | 322 | 2020 |
| Infant colitis—it's in the genes EO Glocker, N Frede, M Perro, N Sebire, M Elawad, N Shah, ... The Lancet 376 (9748), 1272, 2010 | 305 | 2010 |
| Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy C Claus, C Ferrara, W Xu, J Sam, S Lang, F Uhlenbrock, R Albrecht, ... Science translational medicine 11 (496), eaav5989, 2019 | 225 | 2019 |
| CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies M Bacac, S Colombetti, S Herter, J Sam, M Perro, S Chen, R Bianchi, ... Clinical Cancer Research 24 (19), 4785-4797, 2018 | 196 | 2018 |
| CytoMAP: a spatial analysis toolbox reveals features of myeloid cell organization in lymphoid tissues CR Stoltzfus, J Filipek, BH Gern, BE Olin, JM Leal, Y Wu, ... Cell reports 31 (3), 2020 | 180 | 2020 |
| Antigen availability determines CD8+ T cell-dendritic cell interaction kinetics and memory fate decisions SE Henrickson, M Perro, SM Loughhead, B Senman, S Stutte, M Quigley, ... Immunity 39 (3), 496-507, 2013 | 161 | 2013 |
| PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells L Codarri Deak, V Nicolini, M Hashimoto, M Karagianni, PC Schwalie, ... Nature 610 (7930), 161-172, 2022 | 136 | 2022 |
| Monoclonal T-cell receptors: new reagents for cancer therapy HJ Stauss, M Cesco-Gaspere, S Thomas, DP Hart, SA Xue, A Holler, ... Molecular Therapy 15 (10), 1744-1750, 2007 | 80 | 2007 |
| WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells HJ Stauss, S Thomas, M Cesco-Gaspere, DP Hart, SA Xue, A Holler, ... Blood Cells, Molecules, and Diseases 40 (1), 113-116, 2008 | 77 | 2008 |
| Intravital imaging reveals improved Kupffer cell-mediated phagocytosis as a mode of action of glycoengineered anti-CD20 antibodies CL Grandjean, F Montalvao, S Celli, D Michonneau, B Breart, Z Garcia, ... Scientific Reports 6 (1), 34382, 2016 | 58 | 2016 |
| Generation of multi-functional antigen-specific human T-cells by lentiviral TCR gene transfer M Perro, J Tsang, SA Xue, D Escors, M Cesco-Gaspere, C Pospori, L Gao, ... Gene therapy 17 (6), 721-732, 2010 | 57 | 2010 |
| Importance of B cell co-stimulation in CD4+ T cell differentiation: X-linked agammaglobulinaemia, a human model H Martini, V Enright, M Perro, S Workman, J Birmelin, E Giorda, I Quinti, ... Clinical & Experimental Immunology 164 (3), 381-387, 2011 | 54 | 2011 |
| Combination of T-cell bispecific antibodies with PD-L1 checkpoint inhibition elicits superior anti-tumor activity J Sam, S Colombetti, T Fauti, A Roller, M Biehl, L Fahrni, V Nicolini, ... Frontiers in Oncology 10, 575737, 2020 | 43 | 2020 |
| Fibroblast activation protein α-targeted CD40 agonism abrogates systemic toxicity and enables administration of high doses to induce effective antitumor immunity E Sum, M Rapp, P Fröbel, M Le Clech, H Dürr, AM Giusti, M Perro, ... Clinical Cancer Research 27 (14), 4036-4053, 2021 | 40 | 2021 |
| The Type II Anti‐CD20 Antibody Obinutuzumab (GA101) Is More Effective Than Rituximab at Depleting B Cells and Treating Disease in a Murine Lupus Model AD Marinov, H Wang, SI Bastacky, E van Puijenbroek, T Schindler, ... Arthritis & Rheumatology 73 (5), 826-836, 2021 | 35 | 2021 |
